SAB Biotherapeutics, Inc. Warrant (SABSW) Stock Price
SABSWStock
$0.03
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta0.42
SABSW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)5.34%
Price vs S&P 500 (4W)156.46%
VGM Score68.27
Industry Peers — Biological Products(183)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SABSWSAB Biotherapeutics, Inc. Warrant | — | — | B | $0.03 |
| AMGNAmgen Inc | C | C | B | $432.42 |
| GILDGilead Sciences Inc | C | B | B | $145.68 |
| ARGXargenx SE American Depositary Shares | D | A | B | $1023.21 |
| MRNAModerna, Inc. Common Stock | D | C | A | $137.99 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $207.88 |
| BIIBBiogen Inc. Common Stock | C | D | B | $218.50 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $102.08 |
| NBIXNeurocrine Biosciences Inc | C | B | C | $154.06 |
| EXELExelixis Inc | C | B | B | $54.45 |
| HALOHalozyme Therapeutics, Inc. | C | B | B | $105.35 |
About SAB Biotherapeutics, Inc. Warrant
SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing targeted human polyclonal antibodies using its proprietary DiversitAb platform. The company uses genetically modified cattle to produce human antibodies without relying on human plasma or serum, offering a differentiated manufacturing approach. This technology enables rapid production of high-volume therapeutic antibodies, potentially providing a competitive advantage in immunotherapy development.